Across TCGA pan-cancer cohorts, CROCCP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CROCCP2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CROCCP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CROCCP2 expression acts as an unfavorable survival marker.

CESC, ESCA, and SARC are the cancer types where CROCCP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.091	0.755	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
SARC	OS	Median	All	0.176	0.860	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CROCCP2 tumor-vs-normal RNA expression · all CROCCP2 data types